浙江奥翔药业股份有限公司2025 年半年度报告 公司代码：603229 公司简称：奥翔药业 浙江奥翔药业股份有限公司 2025 年半年度报告 1 / 143 浙江奥翔药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人郑志国、主管会计工作负责人朱丁敏及会计机构负责人（会计主管人员）郑仕 兰声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的 ...

Group 1 - The company reported a revenue of 482 million yuan for the first half of the year, representing a year-on-year decrease of 2.14% [1] - The net profit attributable to shareholders was 169 million yuan, showing a year-on-year decline of 5.83% [1] - The basic earnings per share stood at 0.2 yuan per share [1]

证券代码：603229 证券简称：奥翔药业 公告编号：2025-037 浙江奥翔药业股份有限公司 2025 年半年度 募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 (一) 2020 年度非公开发行股票募集资金 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准浙江奥翔药业股份有限公司非公开发 行股票的批复》（证监许可〔2020〕2694 号）核准，公司非公开发行人民币普 通股（A 股）股票 15,206,372 股，发行价为每股人民币 27.62 元，募集资金总 额 419,999,994.64 元，扣除发行费用（不含税）12,059,628.63 元后，实际募 集资金净额为 407,940,366.01 元。上述募集资金净额已于 2020 年 12 月 8 日全 部到位，天健会计师事务所(特殊普通合伙)已对公司本次非公开发行股票的资金 到位情况进行了审验，并已出具天健验〔2020〕583 号《验资报告》。 2、募集资金使用和结余情况 | 金额单 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2025-038 投资者可于 2025 年 9 月 2 日(星期二)至 9 月 8 日(星期一)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 board@ausunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 9 日(星期二)15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 浙江奥翔药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告 ...

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Group 1 - As of August 18, 2025, the stock price of Aoxiang Pharmaceutical closed at 11.34 yuan, with an increase of 0.08 yuan, representing a rise of 0.71% from the previous trading day [1] - The stock opened at 11.24 yuan, reached a high of 11.39 yuan, and a low of 11.14 yuan, with a trading volume of 275,760 hands and a total transaction amount of 311 million yuan [1] - On the morning of August 18, Aoxiang Pharmaceutical's stock experienced a rapid rebound within 5 minutes, with an increase exceeding 2%, peaking at 11.39 yuan and a transaction amount of 42.63 million yuan [1] Group 2 - Aoxiang Pharmaceutical's main business includes the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates, covering various fields such as anti-infection, cardiovascular, and anti-tumor [1] - The company operates in sectors including chemical pharmaceuticals, innovative drugs, and CRO (Contract Research Organization) [1] Group 3 - On August 18, the net outflow of main funds was 17.70 million yuan, with a cumulative net outflow of 180 million yuan over the past five days [1]

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Group 1: New Stock Offerings - Shenke Co., Ltd. (002633) has a tender offer period from July 29, 2025, to August 27, 2025[1] - ST Kelly (300326) has a tender offer period from July 17, 2025, to August 15, 2025[1] - ST Zitian (300280) has a tender offer period ending on July 21, 2025[1] Group 2: Market Alerts - Xizang Tourism (600749) reported severe abnormal fluctuations on July 31, 2025[1] - Tianlu Convertible Bonds (110060) announced significant market activity on July 30, 2025[1] - ST Suwu (600200) experienced unusual trading patterns on July 30, 2025[1] Group 3: Additional Announcements - Happiness Blue Ocean (300528) issued a notice on July 30, 2025, regarding market conditions[1] - Common Pharmaceutical (300966) provided updates on August 1, 2025, related to stock performance[1] - Dongjie Intelligent (300486) released a statement on August 1, 2025, concerning market volatility[1]

创新药概念股集体走低，奥翔药业（603229）触及跌停，科兴制药跌超10%，塞力医疗（603716）、德 展健康（000813）、海创药业跌幅居前。 ...

Group 1 - Pharmaceutical stocks continued to decline in early trading, with companies like Kexing Pharmaceutical and Bioventure dropping over 11% [1] - Other companies such as Aoxiang Pharmaceutical, Shenlian Biological, Anke Biotechnology, Zhongsheng Pharmaceutical, and Haichuang Pharmaceutical experienced declines of over 6% [1]